Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban for portal, mesenteric, and splenic vein thrombosis
2014-005162-29Phase 3Completed
- Sponsor
- ASST Sette Laghi
- Start
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of rivaroxaban in portal vein thrombosis (PVT), Mesenteric venous thrombosis (MVT), splenic vein thrombosis (SVT) and 1 more, sponsored by ASST Sette Laghi. Primary endpoint: Major bleeding. Started May 2015; status: completed.
02
Drugs
rivaroxaban
03
Conditions
portal vein thrombosis (PVT)Mesenteric venous thrombosis (MVT)splenic vein thrombosis (SVT)splanchnic vein thrombosis
Beyond the preview
Go deeper on 2014-005162-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005162-29.